CERTIFICATE OF ANALYSIS

PuriLab Analytical

Retatrutide 30 mg

RT-2026-152 Lot IRX301 Analyzed November 20, 2026



TIMELINE

ORDERED
November 18, 2026

RECEIVED
November 20, 2026

ANALYZED
November 20, 2026

SAMPLE

NAME
Retatrutide 30 mg

EXPECTED
Retatrutide

AMOUNT
1 vial, lyophilized powder

TESTING

CLIENT
David D.

TEST TYPE
Content & purity, fentanyl

METHOD
HPLC-UV

CONTENT, HOW MUCH IS IN IT

33.57 mg

Label claim: 30 mg

PURITY, HOW CLEAN IT IS

99.7%

Measured, not estimated. Purity is calculated from the full chromatogram shown above.


FENTANYL

NOT DETECTED

Screening cutoff 20 ng/mL

CHROMATOGRAM

HPLC-UV



- 13.39 min, Retatrutide, 99.7%

ANALYST COMMENTS

White lyophilized powder, purple flip-cap vial, received sealed.

ANALYST SIGNATURE

Max Barrett
Lab Director, PuriLab Analytical
Analysis date: November 20, 2026

VERIFICATION CODE

RT-UCZW-33X7

Verify at purilab.org/verify/RT-UCZW-33X7

SCAN TO VERIFY

RT-UCZW-33X7

Results apply solely to the sample as received and are not representative of any larger lot, batch, or production run. Findings are limited to the analytes stated above. PuriLab Analytical is an independent testing laboratory, is not CLIA certified or ISO 17025 accredited, does not sell or distribute any substance, and makes no representation as to the safety, legality, or fitness of any material for any use.